All posts by medical

Video: COVID-19 Why it Matters, Part 4: Why wash hands/wear mask? – UWGB

This video series features UW-Green Bays Immunologist Brian Merkel on COVID-19 and Why it Matters. This series empowers viewers with knowledge to help them navigate through the pandemic. Merkel has a Ph.D. in Microbiology & Immunology from the Medical College of Virginia. He is an associate professor in UW-Green Bays Human Biology & Biology programs and has an appointment at the Medical College of Wisconsin Department of Microbiology and Immunology. He will be responding to a number of questions related to COVID19 and try to get behind the why its important to be educated in your decision-making as we navigate the pandemic together.

Video Transcript COVID-19 Why it Matters, Part 4: Why wash hands/wear mask?

Brian Merkel, Microbiology and Immunology, talking about Why COVID-19 matters to you.

COVID-19 is a respiratory agent and what that means and why thats important is that it can contaminate surfaces, so we have to be mindful about keeping our hands clean and washing our hands for 20 seconds.

It also means that when we breathe and exhale and when we yell or when we talk and when we cough and we sneeze because this is a respiratory disease, those are all opportunities for the virus to get out in the environment and infect someone else. Given those realities, thats why hand washing becomes very important and its considered to be 20 seconds to be effective. And face coverings very very clearly when both the infected and uninfected when both parties as much face covering and face and mask wearing as we can have the better off were going to be. Because it reduces the ability for the virus to be transmitted and to infect other people.

COVID-19 Why it Matters Video Series:

Visit link:
Video: COVID-19 Why it Matters, Part 4: Why wash hands/wear mask? - UWGB

Sheffield immunologists part of unprecedented national effort to search for answers on Covid-19 – Latest – News – University of Sheffield News

28 August 2020

Three new UK-wide studies will receive 8.4 million from UK Research and Innovation (UKRI) and the National Institute for Health Research (NIHR) to understand immune responses to the novel coronavirus, SARS-CoV-2.

The largest of these is the UK Coronavirus Immunology Consortium (UK-CIC), which receives 6.5 million in funding. It will bring together scientists at the University of Sheffield with immunologists at 16 other UK universities to investigate the following:

Specifically, the Sheffield team will study two main areas:

The contribution of the University of Sheffield to UK-CIC reflects the notable expertise across the University in both myeloid and T cell biology, and infectious diseases.

Together, it is hoped the studies of the UK-CIC will significantly improve our understanding of this new virus and thus treatment outcomes for patients. They may also inform the development of vaccines and new therapies for Covid-19.

The project will use samples and data from major UK Covid-19 projects already underway, and funded by UKRI and NIHR, including ISARIC-4C (characterising and following more than 75,000 hospitalised patients with Covid-19) and the genomic studies COG-UK (sequencing the SARS-CoV-2 virus genomes) and GenOMICC (sequencing the genomes of people with Covid-19).

The Sheffield team is led by Professor Claire Lewis from the Department of Oncology and Metabolism and Professor Sarah Rowland-Jones, Dr Thushan de Silva and Professor Endre Kiss-Toth from the Department of Infection, Immunity and Cardiovascular Disease.

Claire Lewis, Professor of Molecular and Cellular Pathology at the University of Sheffield, said: We are delighted to be able to contribute to this exciting new immunology consortium. Pooling our expertise and resources in this way will accelerate our understanding of how this coronavirus affects the immune system, and thus how we can defeat it.

The University of Sheffield has a rich heritage of pioneering research to fight infectious disease. In 1941 Sir Howard Florey, former Chair of Pathology at the University of Sheffield, conducted the first ever clinical trials of penicillin a drug which would go on to save more than 82 million lives worldwide.

Pooling our expertise and resources in this way will accelerate our understanding of how this coronavirus affects the immune system, and thus how we can defeat it

Professor Claire Lewis, University of sheffield

Dr Thushan de Silva, Senior Clinical Lecturer in Infectious Diseases at the University of Sheffield, said: We are excited to be working with colleagues across the consortium to characterise the nature and durability of immunity after Covid-19. This work will be key to understanding what immune responses are important in protecting people from re-infection as we move into the next phases of the pandemic.

The UK-CIC consortium is led nationally by Professor Paul Moss at the University of Birmingham, who said: The UK is a world leader in immunology research and its an honour to lead this consortium to deliver a coordinated and agile national research programme to build our knowledge of this disease, which will translate into meaningful benefits for patients. There is so much that we still need to learn about how the novel coronavirus interacts with our immune systems and, with this investment, we have a unique opportunity to answer these key questions and hasten effective pandemic control.

The Humoral Immune Correlates of Covid-19 (HICC) consortium will receive 1.5 million to study the humoral immune response molecules produced by the immune system to fight infection, including antibodies. They will focus on two groups: NHS workers in collaboration with SIREN to track immunity over 12 months, and hospitalised patients.

Both the UK-CIC and HICC have been given urgent public health research status by the Department of Health and Social Care to prioritise their delivery by the health and care system.

The third study will specifically focus on the key features of fatal Covid-19 and the impact the virus has upon the lungs and other vital organs. The project, titled Inflammation in Covid-19: Exploration of Critical Aspects of Pathogenesis, or ICECAP, will receive 394,000.

Chief Medical Officer for England and Head of the NIHR, Professor Chris Whitty, said: Understanding how our immune systems respond to Covid-19 is key to solving some of the important questions about this new disease, including whether those who have had the disease develop immunity and how long this lasts, and why some are more severely affected.

This investment by the NIHR and UKRI will help immunology experts to discover how our immune systems respond to SARS-CoV-2, including our T cell response. This is vital information to help prevent and treat the disease.

These studies build on the UKs world-class expertise and capability in global health and infectious disease that has already shaped our understanding of the pandemic and is informing measures to tackle it.

The full list of research institutions include the University of Birmingham, University of Bristol, University of Cambridge and Wellcome Sanger Institute, UCL, Kings College London, Imperial College London, University of Liverpool, University of Manchester, Newcastle University, University of Oxford, University of Sheffield, University of York, Cardiff University, University of Dundee, University of Edinburgh, University of Glasgow and the Bradford Institute for Health Research.

The University of Sheffield

With almost 29,000 of the brightest students from over 140 countries, learning alongside over 1,200 of the best academics from across the globe, the University of Sheffield is one of the worlds leading universities.

A member of the UKs prestigious Russell Group of leading research-led institutions, Sheffield offers world-class teaching and research excellence across a wide range of disciplines.

Unified by the power of discovery and understanding, staff and students at the university are committed to finding new ways to transform the world we live in.

Sheffield is the only university to feature in The Sunday Times 100 Best Not-For-Profit Organisations to Work For 2018 and for the last eight years has been ranked in the top five UK universities for Student Satisfaction by Times Higher Education.

Sheffield has six Nobel Prize winners among former staff and students and its alumni go on to hold positions of great responsibility and influence all over the world, making significant contributions in their chosen fields. Global research partners and clients include Boeing, Rolls-Royce, Unilever, AstraZeneca, Glaxo SmithKline, Siemens and Airbus, as well as many UK and overseas government agencies and charitable foundations.

UK Research and Innovation works in partnership with universities, research organisations, businesses, charities, and government to create the best possible environment for research and innovation to flourish. We aim to maximise the contribution of each of our component parts, working individually and collectively. We work with our many partners to benefit everyone through knowledge, talent and ideas.

For further information please contact:

Amy HuxtableMedia Relations OfficerThe University of Sheffield0114 222 9859a.l.huxtable@sheffield.ac.uk

Go here to see the original:
Sheffield immunologists part of unprecedented national effort to search for answers on Covid-19 - Latest - News - University of Sheffield News

Cancer Immunology And Oncolytic Virology Market Investigation Highlights Growth Trends in COVID-19 the Coming Years – Kentucky Journal 24

The global cancer immunotherapy market should reach $96.5 billion by 2021 from $73.0 billion in 2016 at a compound annual growth rate (CAGR) of 5.7%, from 2016 to 2021.

Report Scope:

The scope of this report covers current cancer immunotherapy markets for most common cancers. The market segments included in this report are therapeutic monoclonal antibodies (with special focus on checkpoint inhibitors), synthetic interleukins, interferons, and colony-stimulating factors; small kinase inhibitors of cancer-related targets; protective and therapeutic cancer vaccines; and adoptive cell therapies. This report also covers treatments that are in development for late-stage and early-stage oncolytic viruses. Detailed epidemiological information, discussion of incidence and mortality trends, overview of regulatory landscapes, and analysis of market shares for leading products and companies are also included in this report.

Request For Report sample @ https://www.trendsmarketresearch.com/report/sample/11805

Report Includes:

An overview of the global markets for cancer immunotherapies and oncolytic virology. Analyses of global market trends, with data from 2015, 2016, and projections of compound annual growth rates (CAGRs) through 2021. Analyses of factors influencing market demand, such as clinical guidelines, demographic changes, and market saturation. Information covering the latest trends, market structure, market size, key drug segments, and trends in technology. Coverage of colony stimulating factors (CSFs), interferon alfa and gamma products, interleukin products and therapeutic monoclonal antibodies, including antibody conjugates, cancer vaccines, and other cancer treatment immunology products. Technological discussions, including the current state, newly issued patents, and pending applications. Profiles of leading companies in the industry.

Report Summary

Cancer is a disease with global implications. There are many different types of cancer, of which the most common types include lung, breast, colon and rectal, stomach, head and neck, prostate, cervical, melanoma, and ovarian cancer, as well as leukemia. Cancer is a genetic disease that is conventionally treated by surgery, radiation therapy, chemotherapy, hormonal therapy, and immunotherapy. Surgery is the mainstay treatment for all cancers. Usually surgery is complimented with radiation or chemotherapy to ensure the clearance of all residual cancer. Despite the advances in treatment, cancer has great plasticity; therefore, after a certain time the effects of treatment fade and cancer returns with acquired resistance. Combination therapy, using multiple modalities including surgery and pharmaceutical or radiation therapy, improves response to treatment.

Radiation and chemotherapy have many side effects. Biological treatment options provide less impactful treatment of cancer. Immunotherapy is a type of biological therapy and it incorporates elements of the immune system in cancer treatment. The immune system has various types of cells and proteins that detect and act upon signs of a disease or infection by harmful and foreign substances such as microbes, bacteria and viruses. The immune system differentiates the bodys own cells and tissues through an evolutionary bar-coding system. This system helps the immune system understand encountered foreign substances as nonself. Cancer cells are recognized as nonself as well. The immune system monitors the body for cancer and destroys when it detects a malignancy. Cancer cells can avoid being recognized by the immune system and develop resistance through numerous methods.

Since the early 1900s, the connection between cancer and the immune system has caught the attention of various scientists and medical practitioners. Although the early studies were bluntly done without current technological and scientific tools, they nonetheless shed insights leading to the development of the first monoclonal antibodies and to the use of biologically derived synthetic interleukins and interferons. After many decades of research, immunotherapy finally emerged as a fully functionalclinical area in the 1990s. Since then, the cancer therapeutics landscape has changed dramatically.

With the stream of product approvals in recent years, the global immunotherapy market has reached its current value. In 2015, the global cancer immunotherapy market hit $65 billion. The current immunotherapy market contains several blockbuster products reaching their end-of-market exclusivities; however, the market is mostly comprised of newly introduced and expensive therapies. In 2016, the market expanded by more than 10% over the previous year, reaching $73 billion. During the period of 2016 through 2021, the global cancer immunotherapy market is forecast to grow by a 5.7% compound annual growth rate (CAGR), reaching $96.5 billion in 2021.

The strongest growth is expected to occur in checkpoint-inhibitor drugs with a 19.4% CAGR during the forecast period. Immunomodulators are anticipated to show the second-highest growth rates among immunotherapy products, with an 8.4% CAGR during the same period. The combined sales from both segments are expected to make up for nearly one-third of the market, with a combined sales value of $28 billion in 2021. Checkpoint inhibitors are virtually comprised of monoclonal antibodies; however,they are assessed separately due to their immense commercial and clinical significance. Sales from other therapeutic antibodies accrued to $28 billion in 2016, and this value is expected to remain relatively constant through 2021, due to several patent expiries, pressure from anticipated generic entries, and newly introduced classes of drugs expected by 2021.

More Info of Impact Covid19 @ https://www.trendsmarketresearch.com/report/covid-19-analysis/11805

Read more here:
Cancer Immunology And Oncolytic Virology Market Investigation Highlights Growth Trends in COVID-19 the Coming Years - Kentucky Journal 24

What sewage can tell us about the spread of COVID-19 – High Country News

The sewer is the last stop for Bozeman, Montanas waste, but lately, its the first one for Blake Wiedenhefts work. An associate professor of microbiology and immunology at Montana State University, Wiedenheft has joined other virologists, epidemiologists and immunologists as a member of the universitys COVID-19 task force.

Back in March, a colleague mentioned testing wastewater for evidence of COVID-19 in human waste. The next day, Wiedenheft drove down to Bozemans wastewater treatment plant to see if he could grab a sample. Given how few cases there were in the area at the time, and that 6 million gallons of water flow through the plant daily, he wasnt sure if the virus would be detectable. But Wiedenheft immediately found evidence of it and it kept appearing in the four samples he analyzed over the next 10 days. Wiedenheft worked with local officials to continue regular testing as Bozeman became one of the first cities in the world to look to sewage for answers. Now, cities across the Western United States are sampling wastewater for evidence of SARS-CoV-2 as a potential early warning system for outbreaks. Scientists estimate that up to45% of people infected with the virus show no symptoms. Given that asymptomatic people are less likely to get tested, many cases may go undetected. With many areas experiencing substantial delays in swab test results, daily wastewater testing can give scientists an idea of community infection nearly immediately, Wiedenheft said.

City of Bozeman Wastewater Pre-treatment Coordinator Mark DeWald, left, and Water Reclamation Facility Lab Foreman Josh French, right, separate the housing unit of an autosampler to collect a wastewater sample jug from a Montana State University sewage line collection site.

The autosampler looks like two mini fridges stacked vertically. The top compartment houses a tube and pump, which hoovers up half-cup samples and deposits them into a plastic jug in the cool bottom compartment. Every 24 hours, a sample from this jug is taken to Wiedenhefts lab for testing. Wiedenhefts lab employs the same methods used to analyze COVID-19 nose swab tests: Researchers take RNA whether floating in a liter of wastewater or smeared on a swab and perform a procedure that amplifies the genetic signature of the SARS-CoV-2 virus. That allows researchers to identify the virus.

The challenge of analyzing wastewater, as opposed to a swab, is that RNA samples are such a tiny part of the overall jug of wastewater. Imagine youve got a jar full of jelly beans, and youre dipping into the jar to see if you can find a red jelly bean, said Wiedenheft. If your jar is small, its more likely youre going to scoop up that red jelly bean, but if your jar is big, its less likely, and youre going to have to collect more of the sample to find it. The virus is like the red jelly bean; to get an accurate glimpse into how much virus is in a citys water, scientists have to make sure the samples they collect are representative of its overall water flow. That means taking more frequent samples at peak times in the mornings, when people are starting their routines, or in the evenings, when they are doing chores as well as less frequent samples when the water flow is lower, as it is very early in the morning. Bozemans autosampler collects around three dozen samples daily.

Blake Wiedenheft, associate professor of microbiology and immunology at Montana State University and a member of the universitys COVID-19 task force. Wiedenheft has been working with the City of Bozeman Water Reclamation Facility to monitor the virus.

The upshot of Wiedenhefts lab analyses whether samples are virus positive or negative are posted on the countys public health website. In the 26 samples taken between June and mid-August, the coronavirus was detected every time.

French said they are now experimenting with sampling from specific areas of town, like the hospital and Montana States campus. Engineers have identified their main sewer flow lines and placed mobile samplers just beneath manhole covers, where they collect samples one day a week. As the school year kicks off, MSUs data could track viral spread on campus, while the hospital data could help scientists better understand how their results map on to community spread. We know how much viral protein (Wiedenheft) is detecting in his lab, but how many individuals is that reflective of? asked French.

Researchers have yet to arrive at a definitive answer. Converting wastewater data into an estimate of positive cases requires a key metric scientists are still learning about: how much virus a sick person sheds. That depends on the stage of illness the person is in, as well as how severe the illness is. Because those variables are hard to nail down, Wiedenheft has intentionally avoided reporting such estimates. We dont feel confident enough to make that translation, he said.

But in some cities, officials have released estimates using wastewater data to indicate how many community members are infected. For instance, analyses by Biobot, a wastewater testing startup, estimated that levels of SARS-CoV-2 found in Moscow, Idahos sewage corresponded to 1,800 cases. At the time of the estimate, Latah County, where Moscow is located, had only 46 known cases. (Biobot declined to be interviewed, and its hired communications firm did not answer questions about how the company calculates case estimates. A recent study published by Biobots co-founders and colleagues reported that assumptions about individuals viral load can massively affect these estimates. According to their calculations, assuming infected people have a low viral load leads to an estimate that 5% of the population is infected, whereas assuming a high viral load will lower that estimate to 0.1%.)

It was somewhat reassuring to have another backstop indicator of what was happening.

So far, many local officials have looked to wastewater analyses more as a way to corroborate their knowledge about community viral spread than as a way to estimate case numbers. We wont know how many people in the community have COVID-19 from the methodology, but this data will tell us if trends are going up or down, says Nicole Rowan, clean water program manager at the Colorado Department of Public Health and Environment, which has launched a state-wide wastewater testing effort.

Matt Kelley, health officer at the Gallatin City-County Health Department, said that when his county went through a period of few cases in May, the sewage data gave additional confirmation that spread had slowed. It was somewhat reassuring to have another backstop indicator of what was happening, he said and when positive COVID-19 swab tests rose again, so did levels of SARS-CoV-2 in the water. Kelley said that once cases fall again, it will be helpful to track wastewater as an indicator of undetected community spread. If were not seeing tests in the traditional medical testing, and also not seeing them in the wastewater, thats a validating factor for us.

Ardem Nemudryi, a postdoctoral researcher at Montana State University, uses a bottle top filter to separate SARS-CoV-2 virus RNA from a waste water sample.

As more areas launch wastewater tracking programs, Wiedenheft said theres still one thing needed: a central repository for this data, which could provide a bigger-picture view of viral spread. Over the last few months, Montana has developed several monitoring sites, and some states, like California, Colorado and Wyoming, created their own networks. Its difficult just to compile a list of cities conducting testing, since some key data is private; Biobot said it is working with 400 facilities, but declined to provide additional information, including how many cities that corresponds to. Wiedenheft points to Johns Hopkins popular coronavirus tracker as an example of a well-organized health surveillance tool. It would be nice to have a wastewater surveillance website that does the same thing, where you could look at a geographic map and look at whats happening, he said.

Stay up to date on the West with our free newsletter

Thank you for signing up for our Newsletter.

In mid-August, the U.S. Centers for Disease Control and Department of Health and Human Services announced plans for a National Wastewater Surveillance System, a portal to which health departments can submit their wastewater data. After the federal governments changes to a portal tracking hospital data lead to widespread reporting delays and data inconsistencies, its unclear how the database will fare and whether this new initiative provides funding to areas conducting testing. Wiedenhefts funding goes through August, and hes unsure where the money will come from after that. If wastewater sampling is important and I think it is, since theres plenty of evidence to suggest its really the only real-time indicator in the community then it seems important to have funding to support this ongoing effort, he said. Thats imperative to be able to manage a pandemic.

Note: The section of this story on assumptions about how viral loads impact estimates of community spread has been updated to reflect that assuming a low viral load would mean 5% of the population hasSARS-CoV-2 and that a high viral load could mean as little as 0.1% are infected.

Jane C. Hu is a contributing editor for High Country News and an independent journalist who writes about science, technology and the outdoors. She lives in Seattle. Email her at [emailprotected]or submit a letter to the editor.

Read more:
What sewage can tell us about the spread of COVID-19 - High Country News

Emergex Vaccines forms US subsidiary (Emergex USA) by acquisition of laboratories, technology and assets of US-based T cell specialist biotech ImmProN…

Acquisition brings critical technical pre-clinical vaccine development capabilities in-house and establishes US based Emergex subsidiary

Emergex uniquely develops novel 100% synthetic set-point T cell priming vaccines to address some of the worlds most pathogenic infectious diseases

Current COVID-19 pandemic and ongoing threat of pandemic flu demonstrate urgent global need for safe, effective vaccines which can be rapidly developed and deployed

Abingdon, UK, 1 September 2020 Emergex Vaccines Holding Limited (Emergex), a company tackling major global infectious disease threats through the development of synthetic set point vaccines which prime the T cell immune response, today announces that it has significantly strengthened its technology platform and formed US subsidiary, Emergex USA, by acquiring the laboratories, technology and assets of US-based biotech ImmProNano Inc. Financial details of the transaction were not disclosed.

ImmProNano (IPN), based in Doylestown, PA is a specialist contract research organization in the field of Human Leukocyte Antigen T cell immunology and immunoproteomics, utilizing state of the art mass-spectrometry to determine Class I major histocompatibility complex expression libraries of viral infected cells. These libraries are critical to the development of vaccines to high pathogen viruses and intracellular bacteria. IPN also has unparalleled expertise in the T cell immunology of infectious disease and T cell vaccine development.

IPN has completed all pre-clinical testing in animals and ex vivo human samples for Emergexs recent vaccine programs including Francisella tularensis, Yellow fever, Zika, Dengue, Influenza and COVID-19.

ImmProNanos laboratory facilities and key employees will now form Emergexs US subsidiary. The team will continue to work closely with Emergexs state of the art UK R&D facility and also form critical interactions with Emergexs other vaccine collaborators at George Mason University, USA and the Institute of Molecular and Cell Biology of Singapore (A*STAR).

Storme Moore-Thornicroft, co-founder and COO of Emergex, commented: ImmProNano has been a trusted partner for several years, their deep expertise in T cell immunology complementing our novel approach to vaccine development. This acquisition establishes a US base and brings together key elements of the vaccine development process in-house, an important next step as we look to advance promising vaccine candidates in areas including Dengue Fever, pandemic flu and other globally important infectious diseases. The critical need for the ability to develop and manufacture potent vaccines in a timely and cost-effective manner has never been clearer and todays agreement ensures Emergex is well placed to meet this goal.

Originally posted here:
Emergex Vaccines forms US subsidiary (Emergex USA) by acquisition of laboratories, technology and assets of US-based T cell specialist biotech ImmProN...

Magenta Therapeutics Appoints Lisa M. Olson as Chief Scientific Officer and Kevin B. Johnson as Senior Vice President, Head of Regulatory and Quality;…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced the appointment of two new executives, Lisa M. Olson, Ph.D., as Chief Scientific Officer and Kevin B. Johnson, Ph.D., as Senior Vice President, Head of Regulatory and Quality. The Company also announced that Jason Ryan will transition from Chief Operating and Financial Officer to a consulting role for personal reasons while a search for his replacement is conducted.

With the additions of Lisa and Kevin to our team, Magenta continues to deepen our technical expertise, bolstering our strong discovery, research, development and regulatory leadership to further our goal of delivering curative immune reset to patients in need, said Jason Gardner, D.Phil., Chief Executive Officer and President, Magenta Therapeutics. We are delighted to welcome Lisa and Kevin on board and look forward to their many contributions to the Magenta mission.

As Chief Scientific Officer, Dr. Olson will provide strategic direction, oversight and execution for Magentas research and discovery efforts. This entails driving research strategy as Magenta continues to optimize its preclinical and clinical pipeline. She will join the executive team and will be a key member of the R&D leadership team.

Dr. Olson is an experienced senior-level pharmaceutical executive, with more than 20 years of experience in research and drug discovery. She comes to Magenta following 15 years in leadership positions at the AbbVie Bioresearch Center, most recently as Vice President, Immunology Discovery and Site Head, where she was responsible for all immunology discovery scientific and portfolio decisions, including new target approval, project advancement and licensing opportunities. Under her leadership, 15 molecules advanced into clinical development, including Upadacitinib that launched last year as Rinvoq. Prior to AbbVie, she served as a Research Fellow and Group Leader in Inflammation & Immunology at Pfizer, Inc. She began her career as an Assistant Professor at Washington University School of Medicine, following a post-doctoral cardiovascular fellowship at the University of Chicago.

Dr. Olson holds a Ph.D. from the University of Illinois at Urbana-Champaign and a Bachelor of Science from Iowa State University.

As Senior Vice President, Head of Regulatory and Quality, Dr. Johnson will lead Magentas global regulatory strategy for the Companys programs across multiple therapeutic areas. He will also be responsible for the oversight and accountability for all quality activities to enable Good Practice (GxP) functions across the portfolio. In this role, Dr. Johnson will provide strategic guidance and leadership to members of the R&D leadership team and the regulatory and quality teams for Magentas portfolio for all phases of product lifecycle.

Dr. Johnson bring years of regulatory, quality assurance and development leadership, coming to Magenta from Imara, Inc., where he served as Senior Vice President, Regulatory Affairs, Quality and Pharmacovigilance, leading successful requests for several regulatory designations with the U.S. Food and Drug Administration (FDA). Prior to his time at Imara, Dr. Johnson led global regulatory strategy and implementation for breakthrough therapy-designated rare disease development programs at Vtesse, later acquired by Sucampo. He also served as Director, Global Regulatory Affairs for Rare Diseases and Gene Therapies at GlaxoSmithKline, where he was part of on the international regulatory team for the European approval of the gene therapy Strimvelis for ADA-SCID, and subsequently secured Regenerative Medicine Advanced Therapy (RMAT) designation for a retinal gene therapy product.

Dr. Johnson holds a Ph.D. in Neurobiology from the University of North Carolina (UNC) School of Medicine; a Master of Business Administration from the Kenan-Flagler School of Business, UNC; and a Bachelor of Science in Chemistry from the University of South Florida.

Along with these leadership team additions, Magenta also announced today that Jason Ryan, Chief Operating and Financial Officer, will step down from that role at the end of September. He will continue to contribute to Magenta in a consulting capacity, and the Company has commenced a search for a replacement.

Jason has been a dynamic and reliable leader at Magenta since he joined us in 2019, leading finance and operations, contributing to our strategic planning efforts, and spearheading two financings during a period of significant growth, said Gardner. We are truly grateful for his contributions to the patients we seek to serve, our employees and business partners.

About Magenta Therapeutics

Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of immune system reset through stem cell transplant to more patients with autoimmune diseases, genetic diseases and blood cancers. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant world to revolutionize immune reset for more patients.

Magenta is based in Cambridge, Mass. For more information, please visit http://www.magentatx.com.

Follow Magenta on Twitter: @magentatx.

Forward-Looking Statement

This press release may contain forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as may, will, could, should, expects, intends, plans, anticipates, believes, estimates, predicts, projects, seeks, endeavor, potential, continue or the negative of such words or other similar expressions can be used to identify forward-looking statements. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation risks set forth under the caption Risk Factors in Magentas Annual Report on Form 10-K filed on March 3, 2020, as updated by Magentas most recent Quarterly Report on Form 10-Q and its other filings with the Securities and Exchange Commission. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although Magenta believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither Magenta nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Read more from the original source:
Magenta Therapeutics Appoints Lisa M. Olson as Chief Scientific Officer and Kevin B. Johnson as Senior Vice President, Head of Regulatory and Quality;...

This Free MIT Course Has Everything You Need To Know About COVID-19 – Well+Good

The pandemic has brought a barrage of news with so much information it can be overwhelming to understand whats going on (and to understand whats false). A new free online course from the Massachusetts Institute of Technology (MIT) serves to make that easier. COVID-19, SARS-CoV-2 and the Pandemic will walk you through the science of the pandemic with the help of a few familiar experts.

This MIT COVID-19 course is taught by professors Richard Young, PhD,and Facundo Batista, PhD, and will feature weekly guest lecturers like Anthony Fauci, MD. It explains the fundamentals of coronavirus and host cell biology, immunology, epidemiology, clinical disease, and vaccine and therapeutic development. Part of the course will cover lessons from the AIDS pandemic and the ins and outs of viral immunology.

The course will take place every Tuesday from 11:30 a.m. to 12:30 p.m. ET from September 1 through December 8. The course is open to allMIT students, any eligible cross-registered students, and the general public. Though the general public can view the classes, only students registered through the university will be able to ask questions.

To watch it live, click this link and enter the password mit-covid. If you miss a class, head to this page to view a recording. And be prepared to learn from professors at the top of their game.

Dr. Young is a geneticist who explores how and why gene expression differs in healthy versus diseased cells. He received his PhD from Yale University. In 2006, Scientific American recognized him as one of the top 50 leaders in science, technology and business. Hes also won a Burroughs Wellcome Scholarship, the Chiron Corporation Biotechnology Research Award, and Yales Wilbur Cross Medal. He has served as an advisor to Science magazine, the National Institutes of Health, and the World Health Organization.

Dr. Batista is a professor of microbiology and immunology at Harvard Medical School and the associate director of the Ragon Institute of Massachusetts General Hospital, MIT, and Harvard. He received his PhD from the International School of Advanced Studies in Trieste, Italy. He has served on the editorial boards of various journals, including Science. He is also the recipient of the Royal Society Wolfson Research Merit Award and a fellow of the UK Academy of Medical Sciences. In 2018, he was elected a fellow of the American Academy of Microbiology.

According to the syllabus, the course will cover:

Dr. Fauci will be a guest lecturer at the class covering the Insights from the COVID-19 pandemic on September 22. Dr. Fauci has served as the director of the National Institute of Allergy and Infectious Disease since 1984. He oversees an extensive portfolio of research to prevent, diagnose, and treat established infectious diseases such as HIV/AIDS, respiratory infections, diarrheal diseases, tuberculosis, and malaria.

Additional guest faculty include: Nobel laureate and biologist David Baltimore, PhD; neurosurgeon Victoria Clark, MD, PhD; immunologist Kizzmekia Corbett, PhD; biologist Britt Glaunsinger, PhD; immunobiologist Akiko Iwasaki, PhD; geneticist, molecular biologist, and mathematician Eric Lander, PhD; epidemiologist Michael Mina, PhD; molecular immunologist Michel Nussenzweig, MD, PhD; Shiv Pillai, MD, PhD; immunologist Arlene Sharp MD, PhD; immunologist Skip Virgin MD, PhD; and internal and infectious disease physician Bruce Walker, MD, PhD.

Excerpt from:
This Free MIT Course Has Everything You Need To Know About COVID-19 - Well+Good

$10 million in grants aimed at preventing organ rejection after transplantation Washington University School of Medicine in St. Louis – Washington…

Visit the News Hub

Researchers to study how immune cells respond after lung, heart transplants

Daniel Kreisel, MD, PhD, (right) the surgical director of lung transplantation at Washington University School of Medicine in St. Louis and Barnes-Jewish Hospital, is a principal investigator of two grants from the National Institutes of Health (NIH) totaling $10 million to study the prevention of organ rejection after transplantation. Kreisel is shown operating on a lung transplant patient with Varun Puri, MD, an associate professor of surgery and the associate surgical director of the lung transplant program.

Transplant surgeons and researchers at Washington University School of Medicine in St. Louis have received two grants totaling $10 million from the National Institutes of Health (NIH) to study how immune cells contribute to organ rejection, with the aim of improving the viability of organs after transplant.

A $7.7 million program project grant from the National Institute of Allergy and Infectious Diseases funds research to understand the immunological basis of lung transplant rejection.

And the National Heart, Lung, and Blood Institute awarded nearly $2.6 million to aid studies of the immune systems role in heart transplant rejection.

The ultimate goal is to improve the long-term outlook for lung and heart transplant patients, said Daniel Kreisel, MD, PhD, the surgical director of lung transplantation at the School of Medicine and Barnes-Jewish Hospital, and a principal investigator of both NIH grants. It is our hope that through our research, we will gain critical new insight into the immunological underpinnings of transplant tolerance and rejection.

Understanding how immune cells respond to transplanted organs sets the stage for developing novel therapeutic strategies to improve outcomes for transplant patients, said Kreisel, who is the G. Alexander Patterson, MD/Mid-America Transplant Endowed Distinguished Chair in Lung Transplantation.

For lung transplant patients, the risk of organ failure and death is particularly high. Five years after lung transplantation, about half of the lungs are still functioning, according to the U.S. Organ Procurement and Transplantation Network. This compares with five-year organ survival rates of about 70% for heart, liver and kidney transplants.

Uncovering the basis for the poor survival of lung transplant recipients should also give us new insight into the causes of other inflammatory diseases that affect the lung, said Andrew Gelman, PhD, a professor of surgery, and of immunology and pathology at Washington University and the Jacqueline G. and William E. Maritz Endowed Chair in Immunology and Oncology.

The funding will support three projects led by Kreisel, Gelman and Alexander S. Krupnick, MD, a professor of surgery and director of the lung transplant program at the University of Maryland that examine different immunological aspects of lung transplant tolerance. This refers to the ability of the immune system to recognize a transplanted lung as the bodys own.

Often, lung transplant remains the only option for patients with end-stage lung disease, a condition that can be brought on by emphysema, pulmonary fibrosis, cystic fibrosis and other lung disorders. Unlike other organs, lungs constantly are exposed to whatever is in the environment, including bacteria, viruses and air pollution. Such fragility contributes to the increased risk of chronic rejection and organ failure.

Also playing a key role in the research is Wenjun Li, MD, an associate professor of surgery and director of microsurgery in the Thoracic Immunobiology Laboratory. He is highly regarded among transplant scientists for developing microsurgical and imaging methods that have advanced the understanding of lung and heart transplantation.

For heart transplant patients, receiving a new heart is one of the most viable options for end-stage cardiovascular disease. About 3,550 people received a heart transplant from a deceased donor in 2019, according to the U.S. Organ Procurement and Transplantation Network.

However, heart transplant success can be threatened when the donor heart doesnt work properly. This complication called primary graft failure typically occurs in the early days following surgery and can prevent a newly transplanted heart from supplying enough blood to the bodys vital organs.

Current treatments have focused on targeting immune cells in the recipients heart. These have many side effects and are only modestly effective, said Kory J. Lavine, MD, PhD, a Washington University associate professor of medicine in the Cardiovascular Division and also one of the principal investigators. Our research will focus on alternative approaches based on targeting immune pathways and cell populations in the donor heart. We hope that insight gained from the research will result in new therapies that will increase donor heart availability and improve survival after heart transplantation.

Washington University School of Medicines 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

See the rest here:
$10 million in grants aimed at preventing organ rejection after transplantation Washington University School of Medicine in St. Louis - Washington...

Breakthrough antibodies test to detect COVID-19 cases launches in Birmingham – University of Birmingham

The test was designed to detect all three immunoglobulins produced by the body to optimise the sensitivity and to increase detection at the earliest possible stage after exposure to the virus.

A new test to detect COVID-19 antibodies in people with mild symptoms has been launched by The Binding Site in collaboration with the University of Birmingham's Clinical Immunology Service

The unique SARS-CoV-2 Antibody ELISA has been developed to identify individuals who have had a mild, non-hospitalised disease course following SARS-CoV-2 exposure. This latest development has brought together the Binding Site's extensive experience in developing highly precise, accurate blood tests with the expertise of leading immunology and immunity experts at the University of Birmingham

The new test specifically detects antibodies (IgG, IgA and IgM) to the SARS-CoV-2 trimeric spike protein, which is an important protein for the virus infectivity. The test was designed to detect all three immunoglobulins produced by the body to optimise the sensitivity and to increase detection at the earliest possible stage after exposure to the virus.

Professor Adam Cunningham, Professor of Functional Immunity at the University of Birmingham explains: Humans make three types of antibodies Anti-IgM, IgG and IgA. IgM tends to appear first, and IgG and lgA tend to appear later. By combining all three The Binding Site test is able to detect COVID-19 infection in people who have only mild symptoms of the disease.

The CE-marked ELISA test is simple to use and provides up to 93 test results in 60-90 minutes. The collaboration has shown that as well as through saliva or venous blood samples, the test can also detect antibodies in a dried blood spot. This means that the test can be developed into a finger prick test for home use, offering a more accurate testing capability in homes, businesses, airports as well as GP surgeries and hospitals in the UK and worldwide including low and middle income countries

Dr Stephen Harding, Chief Scientific Officer at The Binding Site said: We set out to develop a test with the University of Birmingham that would detect COVID-19 early, and validated the test in a non-hospitalised population that had mild symptoms which is the largest target population for COVID-19 testing - and we designed the testing kit so it can be used by any laboratory in the world.

The test was developed using over 800 blood samples taken from people who had mild to moderate disease. The test is already being used in many of the clinical studies conducted through the University of Birmingham including those focused on health care workers.

Charles de Rohan, CEO of The Binding Site, commented: The long-standing partnership with the University of Birmingham has brought together unrivalled academic, clinical and commercial expertise, and the combined team worked together seamlessly and quickly to deliver this unique and forward thinking test in record time.

Professor Alex Richter, Professor of Clinical Immunology at the University of Birmingham, who led the test development team, commented: There are two things to get right in an antibody test - which antibodies are we looking for, and what are they recognising? Testing for IgM, IgG and IgA antibodies to the spike protein should give an advantage in terms of early and accurate detection of people with recent exposure, who are not showing symptoms.

The Binding Site has provided free kits to support work in developing countries where the disease continues to spread quickly and is impacting on children through Paediatric Multisystem Inflammatory Syndrome (PIMS). The test has been submitted for rapid FDA approval and is expected to be available in quantities of over 2 million tests per month.

For more information please contact Sophie Belcher, Communications Manager, University of Birmingham, on +44 7815607157. Alternatively, contact the Press Office out of hours on +44 (0)7789 921165.

To hear more about the project please follow this link towatch a video

About the University of Birmingham

The University of Birmingham is ranked amongst the worlds top 100 institutions, and its work brings people from across the world to Birmingham, including researchers and teachers and more than 6,500 international students from nearly 150 countries.

About The Binding Site

Binding Site leads the way in specialist protein diagnostics. Built on strong scientific foundations with extensive expertise in antibody specificity technology, Binding Site gives clinicians and laboratory staff the tools to significantly improve diagnosis and management of patients across a range of cancers and immune system disorders.

The facility in Birmingham, UK, is their global headquarters, employing over 750 of its 1,100 total staff and housing all product development, manufacturing, global distribution and marketing. The Binding Site has a direct presence in over 25 countries and product sales through business partners in more than 100 countries.

Excerpt from:
Breakthrough antibodies test to detect COVID-19 cases launches in Birmingham - University of Birmingham